Changes to the Leadership of Boehringer Ingelheim’s Corporate Department Medicine
Ingelheim, Germany – 10 September 2018 – Boehringer Ingelheim today announced that Dr Christopher Corsico, Senior Vice President, Corporate Division Medicine and Chief Medical Officer, will be leaving Boehringer Ingelheim to pursue his career outside of the company effective 31 December 2018. Dr Thor Voigt, currently Medical Director Germany, has agreed to assume the leadership of the Corporate Division Medicine and to become Chief Medical Officer, effective October 1, 2018.
Allan Hillgrove, Member of the Board of Managing Directors with responsibility for the Human Pharma Business Unit said: "We are grateful to Dr Corsico for his valuable contributions during many years of service for Boehringer Ingelheim. He has been instrumental for Boehringer Ingelheim’s drive for medical and patient focus. On behalf of the Board of Managing Directors I wish him all the best for the future." Allan Hillgrove further commented: "We are pleased to appoint Thor Voigt as Chief Medical Officer and Head of our Corporate Division Medicine. Dr Voigt is a highly respected and trusted leader who has taken multiple roles within Boehringer Ingelheim’s medical division in recent years."
Christopher Corsico joined Boehringer Ingelheim in April 1998 as a Pharmacovigilance Physician, followed by the positions of US Pharmacovigilance Head, US Regulatory Head, and Regional Medical Director for North America. In 2012, he became Head of Corporate Division Quality, Regulatory, Pharmacovigilance and Epidemiology (QRPE) and Medicine, before he took over his current role in 2016.
Thor Voigt joined Boehringer Ingelheim in 1992 and was appointed to his current role in 2015. Prior to his current role, Thor was Medical Director in the Netherlands and the USA and Global Head of Clinical Operations. Thor holds a medical degree from University of Mainz, Germany.
Boehringer Ingelheim
Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.
More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com